Across TCGA pan-cancer cohorts, TRBV21OR9-2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRBV21OR9-2 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TRBV21OR9-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV21OR9-2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUSC, UCEC, and LUAD are the cancer types where TRBV21OR9-2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.